Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of hsa-miR-487a in preparing medicine for treating hepatocellular carcinoma or for postoperative prevention of hepatocellular carcinoma

A technology of hsa-mir-487a and drugs, which can be applied in gene therapy, drug combinations, and pharmaceutical formulations, etc., can solve problems such as abnormal expression, abnormal changes, and apoptosis of miRNA, and achieve inhibition of proliferation and metastasis, and promotion of invasion and metastasis and proliferation, improve prognosis

Active Publication Date: 2015-05-27
XIANGYA HOSPITAL CENT SOUTH UNIV
View PDF6 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] In view of the fact that miRNAs are often located at the brittle points of chromosomes that are prone to loss, rearrangement, and amplification, the brittle points of chromosomes where miRNAs are located are prone to deletion, rearrangement, and amplification, which in turn leads to abnormal expression of miRNAs and directly leads to cell proliferation and differentiation. , metastasis, apoptosis and other functions also undergo abnormal changes, inducing the appearance of tumor cells

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of hsa-miR-487a in preparing medicine for treating hepatocellular carcinoma or for postoperative prevention of hepatocellular carcinoma
  • Application of hsa-miR-487a in preparing medicine for treating hepatocellular carcinoma or for postoperative prevention of hepatocellular carcinoma
  • Application of hsa-miR-487a in preparing medicine for treating hepatocellular carcinoma or for postoperative prevention of hepatocellular carcinoma

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 3

[0041] Example 3 Through the statistics of postoperative indicators of patients with liver cancer, it was found that patients with high expression of hsa-miR-487a in postoperative tissues had a poor prognosis, while those with low expression of hsa-miR-487a had better prognosis indicators . It fully demonstrates that hsa-miR-487a can reflect the prognosis and recovery effect of liver cancer patients, and whether there is the possibility of cancer cell metastasis or regeneration. The results obtained are listed in Figure 6 and Tables 1-7. Example 4 Various in vitro experiments were performed on hsa-miR-487a to further confirm its inhibitory effect on the proliferation and metastasis of liver cancer. The results are listed in Figure 7-11 middle. With the support of the above experimental results, hsa-miR-487a was tested in vivo. The experimental process and the obtained results are shown in Example 5. In Example 5, by binding hsa-miR-487a to vivo-Morpholino, the combined...

Embodiment 1

[0059] chip screening

[0060] Firstly, the miRCURYTM Array microarray kit V8.0 chip from Exiqon was used to analyze 30 cases of liver cancer tissues that had undergone hepatocellular carcinoma surgical resection in Xiangya Hospital to detect solitary large liver cancer (SLHCC), small liver cancer (SHCC) and nodules. miRNAs expression profile in cancer tissues and paracancerous tissues of NHCC. By comparing the miRNA expression profiles of different subtypes of liver cancer, we found a large number of miRNAs profiles that were differentially expressed between cancer and adjacent tumors, and between different subtypes of liver cancer and adjacent tumors. Among them, the expression of hsa-miR-487a in liver cancer tissues is higher than that in para-cancerous tissues, and its expression level is highly expressed in NHCC with high invasion and metastasis subtypes, while SLHCC and SHCC with weak metastatic ability, the results can be found in figure 1 . Screening by miRNA microar...

Embodiment 2

[0062] Fresh liver cancer tissue and corresponding adjacent non-tumor liver tissue (Adjacent nontuinorous liver tissue, ANLT, 1.0 cm away from the tumor edge) were used for fluorescence real-time quantitative PCR detection of miRNA expression level. Among the 120 fresh HCC specimens, there were 40 small HCCs, 40 nodular HCCs and 40 solitary large HCCs. The defined solitary large liver cancer is characterized by a single mass with capsule formation, large volume (tumor diameter > 5.0 cm) but relatively less venous invasion, and a low recurrence and metastasis rate after surgical resection. Surgical effects and prognosis are good, with unique clinical and molecular pathological features and relatively good tumor biological behavior. A tumor with a diameter of S5.0 cm is considered a small liver cancer, and a tumor with a number of nodules ^2 is a nodular liver cancer[4]. Special attention should be paid to avoiding hemorrhagic and necrotic tissue when collecting specimens. Afte...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides an application of hsa-miR-487a in preparing a medicine for treating a hepatocellular carcinoma or for postoperative prevention of the hepatocellular carcinoma. According to the application, miRNA (micro Ribonucleic Acid) named as hsa-miR-487a has high expression in hepatocellular carcinoma, which is confirmed through research for the first time. By utilizing the characteristic of RNA, a hsa-miR-487a probe is adopted for postoperative prognoses of a patient, and individual treatment in later period is facilitated.

Description

technical field [0001] The present invention relates to an endogenous non-coding small miRNAs, a pharmaceutical composition containing the same, and its new application for the treatment or postoperative prevention of liver cancer, in particular, relates to a hsa-miR-487a for the treatment or postoperative prevention of liver cancer Use in drugs for preventing liver cancer after operation. Background technique [0002] As we all know, hepatocellular carcinoma (HCC, referred to as liver cancer) is the fifth most common tumor in males in the world. It has the characteristics of poor prognosis and high mortality, which seriously threatens the life and health of our people. For example, in 2008, there were 74.83 million new cases of liver cancer in the world, and 69.59 million deaths from liver cancer in the same year, and the incidence rate and mortality rate were almost 1:1. Although in recent years, with the continuous improvement of imaging diagnosis and surgical technology...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K48/00C12Q1/68A61P35/00
Inventor 杨连粤常睿敏
Owner XIANGYA HOSPITAL CENT SOUTH UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com